Vazyme Biotech

since the establishment in 2012, vazyme has been dedicated to our mission "science and technology make a healthier life" to focus on technology innovation and continuously expand the application fields of core technologies in life science. currently, we have a portfolio of over 200 kinds of genetic engineering recombinases, more than 1,000 kinds of high-performance antigens, monoclonal antibodies and other key raw materials, in addition to over 600 finished products. as a r&d based company, we have been holding ourselves to the highest standards of ethics, accountability and professionalism. our global research and development operations make sure we could provide quality products, solutions, and services locally to our customers, and more importantly, to do as much as it can to meet the unmet customers’ needs. for now, we are present in more than 60 countries and regions worldwide to get close to local customers.